FDA Discusses Pilot Program for Single Patient INDs

Drug Industry Daily
A A
The FDA said it plans to reach out to drug manufacturers that turn down oncologists’ requests for single patient investigational new drugs (INDs) through a pilot program designed to restructure applications for expanded access.

To View This Article:

Login

Subscribe To Drug Industry Daily